The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Nektar shed 70% of its workforce as a result and refocused its R&D on NKTR-358, an IL-2 conjugate regulatory T cell stimulator for inflammatory conditions like lupus and atopic dermatitis ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93. The stock’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.34.

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports.

25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV) ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) has announced results from two Phase 1b studies, published in Nature Communications, showing the efficacy of rezpegaldesleukin in treating atopic ...